Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by The Aspen Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Aspen Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Is There Anything GLP-1s Can’t Do?

1:06:55
 
Share
 

Manage episode 520265907 series 2529451
Content provided by The Aspen Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Aspen Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Weight loss and diabetes drugs in the class called GLP-1s have exploded onto the market, starting to put a real dent in the obesity epidemic. And as doctors are gathering more data, it looks like the medications may also provide real benefits for cardiac health, liver disease, kidney function and possibly even addiction and sleep disorders. In this episode, a panel of experts explains how the drugs work, why they’ve been so effective, and how hopeful we might be about other uses. Cedars Sinai cardiologist Martha Gulati joins Nora Volkow, the director of the National Institute on Drug Abuse and Diana Thiara, an obesity expert at UCSF, for a forward-looking conversation about this potentially game-changing medical advancement. Time Magazine health reporter Alice Park moderates the conversation.

  continue reading

573 episodes

Artwork

Is There Anything GLP-1s Can’t Do?

Aspen Ideas to Go

111 subscribers

published

iconShare
 
Manage episode 520265907 series 2529451
Content provided by The Aspen Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Aspen Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Weight loss and diabetes drugs in the class called GLP-1s have exploded onto the market, starting to put a real dent in the obesity epidemic. And as doctors are gathering more data, it looks like the medications may also provide real benefits for cardiac health, liver disease, kidney function and possibly even addiction and sleep disorders. In this episode, a panel of experts explains how the drugs work, why they’ve been so effective, and how hopeful we might be about other uses. Cedars Sinai cardiologist Martha Gulati joins Nora Volkow, the director of the National Institute on Drug Abuse and Diana Thiara, an obesity expert at UCSF, for a forward-looking conversation about this potentially game-changing medical advancement. Time Magazine health reporter Alice Park moderates the conversation.

  continue reading

573 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play